Screener
Vaxcyte, Inc. PCVX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | March 31,2026 | December 31, 2025 |
|---|---|---|
| Total assets | $3,348,308 | $3,002,717 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $63,060 | $70,904 |
| Accrued compensation | 7,986 | 23,000 |
| Accrued contract manufacturing expenses | 134,704 | 74,654 |
| Accrued expenses | 30,247 | 31,068 |
| Operating lease liabilities — current | 6,085 | 6,124 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s accounts payable?
- Vaxcyte, Inc. (PCVX) reported accounts payable of $63.06M in Q1 2026.
- How has Vaxcyte, Inc.'s accounts payable changed year-over-year?
- Vaxcyte, Inc.'s accounts payable increased by 207.4% year-over-year, from $20.51M to $63.06M.
- What is the long-term trend for Vaxcyte, Inc.'s accounts payable?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s accounts payable has grown at a 18.2% compound annual growth rate (CAGR), from $88.03M to $171.79M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Vaxcyte, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude